AHCO — AdaptHealth Corp.

Summary of AdaptHealth (AHCO) Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Full Year Revenue: $3.245 billion, a decrease of 0.5% year-over-year; Q4 revenue was $846.3 million, down 1.2% year-over-year but up 1.7% organically.
• Organic Revenue Growth: 1.7% for both the full year and Q4.
• Adjusted EBITDA: $616.7 million for the full year (19.0% margin) and $163.1 million for Q4 (19.3% margin), impacted by a $14.5 million legal settlement and $10 million in accelerated costs for a new capitated contract.
• Free Cash Flow: $219.4 million for the full year, exceeding guidance; Q4 free cash flow was $79.3 million.
• Net Debt: $1.694 billion, with a net leverage ratio of 2.75x, slightly up from 2.68x in Q3.

2. Strategic Updates and Business Highlights

• Operational Model: Implementation of a new operating model aimed at standardizing processes and improving efficiency.
• Capitated Contract: Closed the largest capitated contract in the industry, expected to serve over 10 million patients. Initial onboarding in December was successful, with smooth transitions noted.
• Patient Census Growth: Records set in sleep health, respiratory health, and wellness at home; diabetes health showed improved retention but flat new starts.
• Acquisitions and Divestitures: Acquired a Hawaii-based HME provider and divested a small infusion asset, focusing on core business strengths.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected between $3.44 billion and $3.51 billion, representing 6% to 8% growth over 2025.
• Adjusted EBITDA Guidance: Projected between $680 million and $730 million, with an expected margin of approximately 20.3%.
• First Quarter 2026 Expectations: Revenue growth of 2% to 3% year-over-year, with adjusted EBITDA margin around 16%.

4. Bad News, Challenges, or Points of Concern

• Legal Settlement: A $14.5 million settlement related to debt collection practices could raise concerns about past compliance issues.
• Goodwill Impairment: A noncash charge of $128 million related to the Diabetes Health segment may indicate valuation concerns.
• Diabetes Health Segment: Although retention improved, new starts remained flat, and the segment faces challenges with reimbursement changes and competitive pressures.
• CapEx Increase: Elevated capital expenditures to support the new capitated contract may impact free cash flow in the near term.

5. Notable Q&A Insights

• Legal Settlement Clarification: Confirmed as final and related to past practices; steps have been taken to prevent future issues.
• Capitated Contract Expenses: Higher-than-expected onboarding expenses were acknowledged, but revenue growth from the contract is also anticipated to exceed initial projections.
• Pipeline for Capitated Agreements: Management is optimistic about future opportunities in capitated contracts, noting ongoing discussions and market interest.
• Diabetes Segment Outlook: Efforts to grow the diabetes sales force are underway, with expectations for improved new starts later in 2026.

Overall, AdaptHealth reported solid operational progress and strategic initiatives, but faces challenges in certain segments and must navigate the implications of past legal issues and a significant goodwill impairment. The company remains optimistic about future growth driven by its new capitated contract and operational improvements.